Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - olanzapine 5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - olanzapine 7.5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - olanzapine 10 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder : the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - olanzapine 15 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - olanzapine 20 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dexcel pharma gmbh (8000867) - chlorhexidinbis(d-gluconat) - insert für parodontaltaschen - teil 1 - insert für parodontaltaschen; chlorhexidinbis(d-gluconat) (04898) 2,5 milligramm

USA - engelsk - NLM (National Library of Medicine)

dexcel pharma technologies ltd. - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 2.5 mg - periochip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. periochip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing. periochip should not be used in any patient who has a known sensitivity to chlorhexidine.

USA - engelsk - NLM (National Library of Medicine)

dexcel pharma technologies ltd. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 20 mg

USA - engelsk - NLM (National Library of Medicine)

dexcel pharma technologies ltd. - donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - donepezil hydrochloride 23 mg - donepezil hydrochloride tablets are indicated for the treatment of dementia of the alzheimer's type. efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. donepezil hydrochloride is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. pregnancy category c there are no adequate or well-controlled studies in pregnant women. donepezil hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of donepezil to pregnant rats and rabbits during the period of organogenesis did not produce any teratogenic effects at doses up to 16 mg/kg/day (approximately 6 times the maximum recommended human dose [mrhd] of 23 mg/day on a mg/m 2 basis) and 10 mg/kg/day (approximately 7 times the mrhd on a mg/m 2 basis), respectively. oral administration of donepezil (1, 3, 10 mg/kg/day) to rats during late gestation and th